Alopecia areata is an autoimmune disease resulting in hair loss that is usually in one or more coin-shaped patches on the face, scalp or other areas of the body that grows hair.
We are recruiting subjects aged 18 to 65 years (inclusive) with Alopecia Areata, to participate in a research study that evaluates the safety of an investigational study drug (IMG-007-202), and how participants with Alopecia Areata react to the study drug when given multiple times.
The research will involve two groups of people who will receive different amounts of a medication called IMG-007. The first group, called Cohort 1, will have six participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 300 mg of the medication, over a period of 4 weeks. The second group, called Cohort 2, will have 24 participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 600 mg of the medication, over a period of 4 weeks.
Each participant will go through three phases during the study. The first is a screening phase that can last up to 5 weeks, the second phase is a 16-week treatment phase, and finally there be an 8-week follow-up phase to monitor the participants progress after the treatment period.
This study will last a period of up to 29 weeks and includes 9 visits + 2 follow up; Visits take approximately 4-5 hrs for drug administration days and 2-3 hours for other visits.
Blood samples will be collected from all participants at each visit.
Skin biopsies (a small piece of skin) will be taken during the study.
Compensation may be provided. Participation in this study will come at no cost to you.
